Group 1 - The primary goal of the "High Income DIY Portfolios" Marketplace service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers seven portfolios designed for income investors, including retirees or near-retirees, featuring 3 buy-and-hold portfolios, 3 rotational portfolios, and a 3-bucket NPP model portfolio [1] - The portfolios include two high-income portfolios, two dividend growth investment (DGI) portfolios, and a conservative NPP strategy portfolio aimed at low drawdowns and high growth [1]

Core Insights - The weight loss therapy market is rapidly growing, with leading drugs like Wegovy and Zepbound gaining significant sales traction [1] - Pfizer has faced multiple setbacks in its attempts to enter the weight loss market, particularly with its candidates danuglipron and lotiglipron [2][3][5] Group 1: Pfizer's Weight Loss Drug Development - Pfizer discontinued lotiglipron after phase 1 studies due to potential liver issues [3] - The danuglipron program faced challenges, with a twice-daily version showing efficacy but high side effects, leading to its abandonment [4] - Pfizer scrapped the danuglipron project entirely after a phase 2 study indicated liver injury in a patient, marking a significant setback [5] Group 2: Future Prospects and Other Opportunities - Despite setbacks in the weight loss market, Pfizer is not exiting this area and will pursue other therapeutic options [6] - Pfizer's oncology market prospects are more promising, bolstered by the acquisition of Seagen for $43 billion, enhancing its cancer treatment capabilities [7][8] - Pfizer reported a 7% year-over-year revenue increase to $63.6 billion and a 69% rise in adjusted earnings per share to $3.11 [9] Group 3: Investment Considerations - Pfizer's strong financial performance and deep pipeline make it an attractive option for investors, despite recent challenges in the weight loss sector [10] - The stock offers a forward yield of 7.8%, with a 54% increase in dividends over the past decade, appealing to dividend-seeking investors [9]

智通财经4月17日电，蒙特利尔银行将默克公司目标股价从96美元下调至89美元；将辉瑞目标价从36美 元下调至30美元。 ...

Pfizer Inc (NYSE: PFE ) has had a troublesome few years after the revenue boom generated by its COVID vaccine. The company was among the few beneficiaries of the need to rapidly vaccinate massive swaths of the global population, competing chieflyRetail investor researching mostly semiconductors and fintech. Some general macro musings. My goal is to bring you timely and digestible research on the stocks that I cover.Analyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either throug ...

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to start Q1, consider joining Out Fox The Street .The vaccine fears now have Pfizer Inc. (NYSE: PFE ) trading down to only $22. The market is now pricing in major fears of lost revenues, with the dividend yield soaring to nearly 8%. MyAnalyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article my ...

Core Viewpoint - Pfizer's stock rose by 1.5% despite the company halting the development of its weight loss drug danuglipron, indicating investor confidence in the company's broader pipeline and strategies [1][2]. Group 1: Company Developments - Pfizer announced the cessation of its investigational weight loss drug danuglipron after a patient experienced a liver injury during trials [2]. - The company has another weight loss treatment, PF-07976016, in phase 2 clinical trials, which is based on a different mechanism [3]. - Analysts suggest that Pfizer may pursue mergers and acquisitions or licensing agreements to enhance its product pipeline [4]. Group 2: Market Reaction - Investors appear to be unfazed by the setback with danuglipron, maintaining confidence in Pfizer's future prospects [5]. - The market may become increasingly impatient with Pfizer, as the company has not been a leader in the pharmaceutical sector since the success of its Comirnaty vaccine during the pandemic [5].

Core Viewpoint - Investors are showing increased interest in Viking Therapeutics following Pfizer's termination of its weight-loss pill development due to drug-induced liver injury, leading to speculation about a potential acquisition by Pfizer to enhance its presence in the weight-loss market [1]. Group 1: Viking Therapeutics - Viking Therapeutics' stock has surged due to speculation surrounding Pfizer's potential acquisition, despite the company experiencing a nearly 50% decline in stock value this year, making it a more attractive target [2]. - Viking is currently developing both oral and injectable GLP-1 drugs, which are in Phase 2 trials, indicating ongoing clinical risks [1][6]. Group 2: Pfizer's Position - Pfizer has alternative assets in the weight-loss market, including two other candidates in clinical development, which may lead the company to focus on its own products rather than pursuing an acquisition of Viking [3][4]. - Financial constraints may hinder Pfizer's ability to acquire Viking, as the company has accumulated substantial debt from previous acquisitions and currently has an estimated M&A firepower of $10-$15 billion, making a large-scale buyout challenging [5][6]. - The failure of danuglipron has delayed Pfizer's entry into the competitive weight-loss market, but the company still has other candidates that could be more viable options [3][4]. Group 3: Market Outlook - Despite setbacks, Wall Street maintains a positive outlook on Pfizer, with a consensus rating of "overweight" and an average price target of $29.41, suggesting a potential upside of about 35% from current levels [7]. - Pfizer's stock offers a high dividend yield of 7.78%, appealing to investors seeking passive income amid recession risks [8].

Core Viewpoint - Pfizer's recent decision to discontinue the development of danuglipron highlights the inherent risks in the drug-development business, with the stock trading approximately 63% below its all-time high while offering a 7.8% dividend yield due to its long-standing dividend-raising streak [1][2]. Drug Development Challenges - The termination of the danuglipron program was due to a liver injury experienced by a patient in a dose-optimization study, emphasizing the unpredictability of drug development [3]. - Despite the setback with danuglipron, Pfizer continues to pursue other weight-management drug candidates, including a GIPR antagonist currently in phase 2 trials [4]. Revenue Concerns - A more pressing issue for Pfizer is the impending loss of patent-protected market exclusivity for Eliquis, which generated $7.4 billion in sales, accounting for 11.6% of total revenue last year [5]. - Eliquis is expected to lose its patent exclusivity in 2026, with generic competition anticipated to enter the U.S. market by 2028 [6]. - The Prevnar vaccine family, contributing over 10% of total sales, is also facing patent expiration, with Prevnar 13 expected to lose exclusivity next year [6]. - Vyndaqel, a treatment for TTR amyloidosis, saw a 64% sales increase to $5.4 billion last year, but it will face competition from new treatments and potential generic options by 2028 [7]. Regulatory Environment - The FDA's recent staff reductions could hinder the drug approval process, raising concerns for Pfizer and the broader industry as they rely on new drug launches to offset revenue losses from expiring patents [8][9]. - The former CDER director's transition to Pfizer's leadership may provide some advantages, but the overall impact of a downsized FDA on drug approvals remains uncertain [9]. Investment Outlook - The pharmaceutical industry may rely on lobbyists to maintain the FDA's drug approval pace, but this reliance is viewed with skepticism [10]. - Pfizer had previously been considered a strong investment due to its recent drug approvals, but the current regulatory environment raises doubts about future growth and the ability to maintain its dividend-raising streak [11][12].

Core Insights - Pfizer has announced the discontinuation of its danuglipron oral GLP-1 weight loss pill, impacting its position in the market and benefiting competitors Eli Lilly, Novo Nordisk, and Viking Therapeutics [2][4]. Group 1: Pfizer's Announcement - Pfizer's danuglipron showed potential efficacy but was discontinued due to a case of potential drug-induced liver injury in a study participant [3]. - The company expressed disappointment but remains committed to advancing other promising programs in the weight loss market [4]. Group 2: Impact on Competitors - Eli Lilly and Novo Nordisk saw their stock prices increase by 2% and 2.7%, respectively, following Pfizer's announcement, as they no longer face competition from danuglipron [2][5]. - Eli Lilly reported total revenues exceeding $45 billion last year, while Novo Nordisk surpassed $44 billion, indicating the significant financial stakes in the GLP-1 market [5]. Group 3: Future Prospects for Viking Therapeutics - Viking Therapeutics' stock surged by 9.9% as it is now positioned to potentially become a major player in the GLP-1 market following Pfizer's exit [2]. - JPMorgan noted that Pfizer's decision is a positive development for Viking, making it a more attractive candidate for partnerships with larger pharmaceutical companies [7]. Group 4: Analyst Insights - Guggenheim lowered its price target for Eli Lilly but maintained a buy rating, citing a near-term catalyst with Q1 earnings expected on May 1, projecting earnings of $4.2 billion on $12.8 billion in revenue [6]. - JPMorgan also highlighted Structure Therapeutics and its ACCG-2671 GLP-1 drug, suggesting it could be the second small molecule oral GLP-1 to market, although both Viking and Structure are not yet profitable [8].

Viking Therapeutics Inc (NASDAQ:VKTX) stock is up 10.1% to trade at $24.42 today, and traded as high as $27.09 earlier in the session. The drugmaker is on the move after Pfizer (PFE) halted the development of its weight-loss pill. Viking has two weight-loss drug candidates that have shown promising results in Phase 1 and 2 trials late last year. Sector peers Eli Lilly (LLY) and Novo Nordisk (NVO) -- two heavy hitters in the weight-loss treatment department -- are also higher today.VKTX is still down 39.3% i ...